Coxiella burnetii (Phase II) Positive Control Sample 3227

$75.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Cost-effective due to standardized reagents
Lyophilized antigens, control antigens as well as positive and negative control sera simplify storage
Suitable screening test to identify acute infections
Compensation of seroprevalences allow high specificity

SKU: 3227 Category: Infectious disease proteins Tags: Coxiella burnetii, protein

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Coxiella burnetii phase I immunoglobulins
species reactivity	Coxiella burnetii (Q fever)
applications	ELISA
assay type	qualitative
available size	lyophilized

Coxiella burnetii (Phase II) Positive Control Sample 3227

kit
Research area Infectious Disease
Storage Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Associated products Coxiella burnetii Phase 2 IgG Control Serum (BC1312G) Coxiella burnetii Phase 2 IgM Control Serum (BC1312M) Coxiella burnetii IgA Phase I ELISA Kit (ESR1311A) Coxiella burnetii IgG Phase I ELISA Kit (ESR1311G) Coxiella burnetii IgG Phase II ELISA Kit (ESR1312G) Coxiella burnetii IgM Phase II ELISA Kit (ESR1312M)

target relevance

human antibody anti-Coxiella burnetii1

Coxiella burnetii

Description
Bacterium that causes Q fever

Structure
Coxiella burnetii is an obligate intracellular bacterial pathogen, and is the causative agent of Q fever. The genus Coxiella is morphologically similar to Rickettsia, but with a variety of genetic and physiological differences. C. burnetii is a small Gram-negative, coccobacillary bacterium that is highly resistant to environmental stresses such as high temperature, osmotic pressure, and ultraviolet light. These characteristics are attributed to a small cell variant form of the organism that is part of a biphasic developmental cycle, including a more metabolically and replicatively active large cell variant form. It can survive standard disinfectants, and is resistant to many other environmental changes like those presented in the phagolysosome.

Diagnosis
The diagnosis of Q fever is performed by the demonstration of specific antibodies directed against Coxiella burnetii. Due to variations in the lipopolysaccharide (LPS) structure on the surface of the pathogen, as the disease enters the chronic state, a serological differentiation of acute from chronic infections is possible. Due to the high sensitivity and specificity, the use of ELISA immunoassays is recommended by the World Health Organization (WHO). Following the regular course of an acute primary infection, specific IgM and IgG antibodies directed against the immunogenic phase 2 antigens can be demonstrated. IgG antibodies directed against phase 2 antigens often persist over several years. In the lead-up to a chronic infection, IgG and IgA antibodies directed against the phase 1 antigens appear, which are of diagnostic value particularly for the diagnosis of Q fever endocarditis

Symptoms
Coxiella burnetii is a gram-negative, aerobic coccobacillus of the Coxiellaceae family. The causative agent of the so called Q fever is extremely infectious and very resistant to environmental factors. <br><br>Approximately half of infected individuals exhibit no clinical symptoms. The most common manifestation following an incubation period of two to three weeks, are mild flulike symptoms with abrupt onset of fever, malaise, severe headache, myalgia, loss of appetite, dry cough, chest pain and chill, more seldom accompanied by gastrointestinal symptoms such as nausea, vomiting and diarrhea. During its course, the disease can progress to an atypical pneumonia, which may result in a life-threatening acute respiratory distress syndrome (ARDS). More seldom, Q fever presents as granulomatous hepatitis with inflammation of the liver. In rare cases, the disease takes a chronic course and presents as an inflammation of the inner lining of the heart muscle (endocarditis) or of the heart sac (pericarditis), which is usually fatal if untreated.

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Coxiella burnetii (Phase II) Positive Control Sample 3227?

The Coxiella burnetii (Phase II) Positive Control Sample 3227 should be stored at -65°C, avoiding freeze/thaw cycles to maintain its stability. It is also recommended to sonicate the sample before use.

Which assay type and application is this Coxiella burnetii (Phase II) Positive Control Sample 3227 intended for?

This product is intended for qualitative ELISA applications, specifically targeting Coxiella burnetii phase I immunoglobulins for use in research related to infectious diseases.

What is the target specificity and species reactivity of the Coxiella burnetii (Phase II) Positive Control Sample 3227?

The product targets Coxiella burnetii phase I immunoglobulins and is reactive with Coxiella burnetii, the causative agent of Q fever.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.